FindTrial
Sign In

An observational study was conducted in many countries to collect data regarding the current treatment practices and their outcomes in a patient with weak immunity who was admitted to the intensive care unit with severe difficulty in breathing for improvement in future treatment practices.

A Multicenter Study to Improve Management and Outcomes In Immunocompromised Patients with Acute Respiratory Failure - EFRAIM 3

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/01/061901
Enrollment
10000
Registered
2024-01-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J960- Acute respiratory failure Health Condition 2: D849- Immunodeficiency, unspecified

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Groupe de Recherche respiratoire en Réanimation Onco Hématologique
Lead Sponsor
Not Any
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1 adult patients 2 admitted to the ICU between 1 Jan 2017 to 31 Dec 2022 3. with acute respiratory failure oxygen dependance more than 6 liter per min to achieve SPO2 more than 92 percentage and or respiratory rate more than 30 per minute and or labored breathing and or the need for non invasive or invasive mechanical ventilation or high flow nasal cannula 4 with a known immunodepression hematological malignancy including autologous and allogeneic stem cell transplant, solid tumor requiring treatments over the last five years, solid organ transplant, immunosuppressive drugs for auto-immune or auto inflammatory disease and primary immunodeficeincy

Exclusion criteria

Exclusion criteria: 1. Patients with isolated HIV infection are not eligible for this study 2. Patients already included in the cohort 3. Patient refuse for consent and data collection 4. Patients deprived of liberty under guardianship or curatorship

Design outcomes

Primary

MeasureTime frame
Mortality risk factors in the short and medium termTimepoint: survival at 3 months of immunocompromised patients after ICU admission—

Secondary

MeasureTime frame
A comparison between different intensive care units in terms of mortality and management strategies.Timepoint: comparison of factor affecting the 90 days mortality;to identify the prognostic factors for day-90 mortality.Timepoint: 90 days from the date of ICU admission—

Countries

Australia, Bangladesh, Belgium, Bhutan, Brazil, Egypt, France, Germany, Greece, Hong Kong, Iceland, India, Italy, Japan, Mexico, Myanmar, Netherlands, New Zealand, Norway, Pakistan, United States of America

Contacts

Public ContactSheila N Myatra

Tata Memorial Hospital

sheila150@hotmail.com9820156070

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026